Skip to main content
  • More from ADA
    • Diabetes
    • Clinical Diabetes
    • Diabetes Spectrum
    • ADA Standards of Medical Care
    • ADA Scientific Sessions Abstracts
    • BMJ Open Diabetes Research & Care
  • Subscribe
  • Log in
  • My Cart
  • Follow ada on Twitter
  • RSS
  • Visit ada on Facebook
Diabetes Care

Advanced Search

Main menu

  • Home
  • Current
    • Current Issue
    • Online Ahead of Print
    • Special Article Collections
    • ADA Standards of Medical Care
  • Browse
    • By Topic
    • Issue Archive
    • Saved Searches
    • Special Article Collections
    • ADA Standards of Medical Care
  • Info
    • About the Journal
    • About the Editors
    • ADA Journal Policies
    • Instructions for Authors
    • Guidance for Reviewers
  • Reprints/Reuse
  • Advertising
  • Subscriptions
    • Individual Subscriptions
    • Institutional Subscriptions and Site Licenses
    • Access Institutional Usage Reports
    • Purchase Single Issues
  • Alerts
    • E­mail Alerts
    • RSS Feeds
  • Podcasts
    • Diabetes Core Update
    • Special Podcast Series: Therapeutic Inertia
    • Special Podcast Series: Influenza Podcasts
    • Special Podcast Series: SGLT2 Inhibitors
    • Special Podcast Series: COVID-19
  • Submit
    • Submit a Manuscript
    • Journal Policies
    • Instructions for Authors
    • ADA Peer Review
  • More from ADA
    • Diabetes
    • Clinical Diabetes
    • Diabetes Spectrum
    • ADA Standards of Medical Care
    • ADA Scientific Sessions Abstracts
    • BMJ Open Diabetes Research & Care

User menu

  • Subscribe
  • Log in
  • My Cart

Search

  • Advanced search
Diabetes Care
  • Home
  • Current
    • Current Issue
    • Online Ahead of Print
    • Special Article Collections
    • ADA Standards of Medical Care
  • Browse
    • By Topic
    • Issue Archive
    • Saved Searches
    • Special Article Collections
    • ADA Standards of Medical Care
  • Info
    • About the Journal
    • About the Editors
    • ADA Journal Policies
    • Instructions for Authors
    • Guidance for Reviewers
  • Reprints/Reuse
  • Advertising
  • Subscriptions
    • Individual Subscriptions
    • Institutional Subscriptions and Site Licenses
    • Access Institutional Usage Reports
    • Purchase Single Issues
  • Alerts
    • E­mail Alerts
    • RSS Feeds
  • Podcasts
    • Diabetes Core Update
    • Special Podcast Series: Therapeutic Inertia
    • Special Podcast Series: Influenza Podcasts
    • Special Podcast Series: SGLT2 Inhibitors
    • Special Podcast Series: COVID-19
  • Submit
    • Submit a Manuscript
    • Journal Policies
    • Instructions for Authors
    • ADA Peer Review
e-Letters: Observations

Sodium–Glucose Cotransporter 2 Inhibitors and Diabetic Ketoacidosis: A Case Series From Three Academic Institutions

  1. Negin Misaghian-Xanthos1,
  2. Afreen I. Shariff2,
  3. Kavya Mekala3,
  4. Loretta R. Fearrington1,
  5. Tracy L. Setji2,
  6. Joseph A. Aloi3 and
  7. John B. Buse1⇑
  1. 1University of North Carolina School of Medicine, Chapel Hill, NC
  2. 2Duke University School of Medicine, Durham, NC
  3. 3Wake Forest School of Medicine, Winston-Salem, NC
  1. Corresponding author: John B. Buse, jbuse{at}med.unc.edu.
  1. N.M.-X., A.I.S., and K.M. contributed equally to this study.

Diabetes Care 2017 Jun; 40(6): e65-e66. https://doi.org/10.2337/dc16-2591
PreviousNext
  • Article
  • Suppl Material
  • Info & Metrics
  • PDF
Loading

Sodium–glucose cotransporter 2 inhibitors (SGLT2i) have recently been associated with diabetic ketoacidosis (DKA). Initial case reports were largely among patients using SGLT2i off label in the setting of type 1 diabetes and were unusual because of limited associated hyperglycemia (1). More recently, the problem has been specifically noted in patients with type 2 diabetes (2). Meta-analysis of data from initial randomized controlled trials of SGLT2i suggests little risk of DKA (<0.1%) in patients with type 2 diabetes (3).

To better define the scope of the problem in clinical practice, we conducted a search of three academic health care systems’ electronic health records. The study was approved by institutional review boards. Patients were selected from all emergency and inpatient encounters between 1 January 2013 and 30 April 2016 that contained the diagnosis codes for ketosis or acidosis (ICD-9 codes: 250.10, 250.11, 250.12, 250.13, 276.2, 790.6; ICD-10 codes: E08.10, E08.11, E09.10, E09.11, E10.10, E10.11, E13.10, E13.11, E11.65, E11.69, E87.2) and had an SGLT2i noted in a medication list. Individuals who met prespecified criteria for DKA with arterial pH <7.3, venous pH <7.27, serum bicarbonate <18 mEq/L, positive urine or serum ketones per institutional laboratory cutoffs, or an anion gap >10 were included.

A total of 11,197 individuals had a prescription for SGLT2i documented in a medication list and 39 individuals met the criteria for DKA. Details are provided in Supplementary Table 1. Of the DKA cases, 74% appeared to have type 2 diabetes. Glucose ≤300 mg/dL was noted at presentation of DKA in 26 of the 39 cases (72%). The mean glucose at presentation was 328 mg/dL, median 266 mg/dL, and range 125–904 mg/dL. With respect to precipitating causes, 49% had nausea/vomiting, although it is unclear if that was a cause, contributor, or consequence of the DKA; 67% had an obvious other precipitating event such as surgery, insulin dose reduction, or decreased oral intake and weight loss.

This is the largest and most comprehensive case series of DKA associated with the use of SGLT2i. Uncertainty about the incidence rate of DKA among SGLT2i-treated patients in our institutions is substantial because we do not have claims data confirming that prescriptions were filled, we likely missed cases that were undiagnosed or incompletely assessed, and some of the cases listed were prescribed SGLT2i by practitioners whose prescribing is not reflected in our electronic health records. The relatively lower presenting glucose observed in the setting of SGLT2i-associated DKA is likely due to the proposed pathologic mechanisms (4). It is unclear if there are specific characteristics that make some patients more predisposed.

DKA in the setting of SGLT2i therapy is unusual in that it disproportionately affects those with type 2 diabetes and often presents with glucose <300 mg/dL, making recognition challenging. We would recommend a high index of suspicion for DKA in patients taking SGLT2i with unexplained malaise or gastrointestinal symptoms and recommend measuring urine or plasma ketones in that setting. While its occurrence is unusual, we should counsel patients on the signs, symptoms, and possible precipitants of DKA even in the setting of type 2 diabetes when prescribing SGLT2i.

Article Information

Acknowledgments. The authors thank the data teams at the North Carolina Translational and Clinical Sciences Institute, Duke Clinical and Translational Science Institute, and Wake Forest Clinical and Translational Science Institute for identifying potential cases from the electronic health records.

Funding. The project described was supported at each of the institutions by the National Center for Advancing Translational Sciences, National Institutes of Health, through Grant Award Numbers UL1-TR-001111, UL1-TR-001420, and UL1-TR-001117.

Duality of Interest. J.B.B.’s institution has received grants and contracts from AstraZeneca, Boehringer Ingelheim, Eli Lilly, Jannsen, Sanofi, and Lexicon Pharmaceuticals to support his efforts as investigator and/or advisor. No other potential conflicts of interest relevant to this article were reported.

Author Contributions. All authors participated in study design, analysis, and drafting and approved the final manuscript submitted. N.M.-X., A.I.S., and K.M. are guarantors of this work and, as such, had full access to all the data at their respective institutions and take responsibility for the integrity of the data and the accuracy of the analysis.

Footnotes

  • This article contains Supplementary Data online at http://care.diabetesjournals.org/lookup/suppl/doi:10.2337/dc16-2591/-/DC1.

  • Received December 4, 2016.
  • Accepted March 6, 2017.
  • © 2017 by the American Diabetes Association.
http://www.diabetesjournals.org/content/license

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license.

References

  1. ↵
    1. Peters AL,
    2. Buschur EO,
    3. Buse JB,
    4. Cohan P,
    5. Diner JC,
    6. Hirsch IB
    . Euglycemic diabetic ketoacidosis: a potential complication of treatment with sodium–glucose cotransporter 2 inhibition. Diabetes Care 2015;38:1687–1693
    OpenUrlAbstract/FREE Full Text
  2. ↵
    1. U.S. Food and Drug Administration
    . SGLT2 inhibitors: drug safety communication - labels to include warnings about too much acid in the blood and serious urinary tract infections [Internet], 4 December 2015. Available from http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm475553.htm. Accessed 17 November 2016
  3. ↵
    1. Erondu N,
    2. Desai M,
    3. Ways K,
    4. Meininger G
    . Diabetic ketoacidosis and related events in the canagliflozin type 2 diabetes clinical program. Diabetes Care 2015;38:1680–1686
    OpenUrlAbstract/FREE Full Text
  4. ↵
    1. Rosenstock J,
    2. Ferrannini E
    . Euglycemic diabetic ketoacidosis: a predictable, detectable, and preventable safety concern with SGLT2 inhibitors. Diabetes Care 2015;38:1638–1642
    OpenUrlFREE Full Text
PreviousNext
Back to top
Diabetes Care: 40 (6)

In this Issue

June 2017, 40(6)
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by Author
  • Masthead (PDF)
Sign up to receive current issue alerts
View Selected Citations (0)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word about Diabetes Care.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Sodium–Glucose Cotransporter 2 Inhibitors and Diabetic Ketoacidosis: A Case Series From Three Academic Institutions
(Your Name) has forwarded a page to you from Diabetes Care
(Your Name) thought you would like to see this page from the Diabetes Care web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Sodium–Glucose Cotransporter 2 Inhibitors and Diabetic Ketoacidosis: A Case Series From Three Academic Institutions
Negin Misaghian-Xanthos, Afreen I. Shariff, Kavya Mekala, Loretta R. Fearrington, Tracy L. Setji, Joseph A. Aloi, John B. Buse
Diabetes Care Jun 2017, 40 (6) e65-e66; DOI: 10.2337/dc16-2591

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Add to Selected Citations
Share

Sodium–Glucose Cotransporter 2 Inhibitors and Diabetic Ketoacidosis: A Case Series From Three Academic Institutions
Negin Misaghian-Xanthos, Afreen I. Shariff, Kavya Mekala, Loretta R. Fearrington, Tracy L. Setji, Joseph A. Aloi, John B. Buse
Diabetes Care Jun 2017, 40 (6) e65-e66; DOI: 10.2337/dc16-2591
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Article Information
    • Footnotes
    • References
  • Suppl Material
  • Info & Metrics
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Is Shelter-in-Place Policy Related to Mail Order Pharmacy Use and Racial/Ethnic Disparities for Patients With Diabetes?
  • Trends in Nontraumatic Lower-Extremity Amputation Among Privately Insured Adults With Diabetes in the U.S., 2004–2018
  • Lower-Extremity Amputation Trends Among People With Diabetes in a Large Urban Environment
Show more e-Letters: Observations

Similar Articles

Navigate

  • Current Issue
  • Standards of Care Guidelines
  • Online Ahead of Print
  • Archives
  • Submit
  • Subscribe
  • Email Alerts
  • RSS Feeds

More Information

  • About the Journal
  • Instructions for Authors
  • Journal Policies
  • Reprints and Permissions
  • Advertising
  • Privacy Policy: ADA Journals
  • Copyright Notice/Public Access Policy
  • Contact Us

Other ADA Resources

  • Diabetes
  • Clinical Diabetes
  • Diabetes Spectrum
  • Scientific Sessions Abstracts
  • Standards of Medical Care in Diabetes
  • BMJ Open - Diabetes Research & Care
  • Professional Books
  • Diabetes Forecast

 

  • DiabetesJournals.org
  • Diabetes Core Update
  • ADA's DiabetesPro
  • ADA Member Directory
  • Diabetes.org

© 2021 by the American Diabetes Association. Diabetes Care Print ISSN: 0149-5992, Online ISSN: 1935-5548.